PA-PMI
9.3.2021 17:02:11 CET | Business Wire | Press release
Project Management Institute (PMI), the world's leading association for project professionals and changemakers, today announced the launch of a new online course dedicated to business transformation, the first in an upcoming series on the same topic. The new course, Organizational Transformation: Foundation, is powered by Brightline® , a PMI initiative, and provides project leaders with the building blocks and fundamental knowledge needed to understand how organizations transform efficiently and effectively. Through nine interactive modules that take under ten hours to complete, project professionals quickly learn what it takes to cultivate and implement significant operational and cultural change within an organization, allowing them to support a company-wide transformation in any industry, from any level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005160/en/
Today, the ability to nimbly transform and adapt has become a necessity for organizations, yet data from McKinsey indicates that 70 percent of large-scale transformation efforts fail to achieve their goals. In response, organizations are evolving beyond the usual top-down approach to transformation and leveraging collective buy-in and support from their entire workforce. According to Brightline’s Strategic Transformation Research , organizations that successfully transform quickly and adeptly are almost two times more likely to place an emphasis on developing internal talent which builds employee commitment to larger organizational goals.
“Businesses today are facing unprecedented disruption. To effectively navigate this everchanging climate, they need to evolve, and to power growth, enterprises should have a gymnast character to transform from within. Enterprises should be engaging employees at all levels instead of solely relying on senior leaders or external consultants,” said Sunil Prashara, President and CEO of PMI. “Transformation isn’t just a C-suite conversation anymore. This new course will impact both businesses and individual project leaders on the building blocks to implementing successful transformation efforts, enabling them to support these initiatives and be true changemakers within their organizations.”
Through this online course, project professionals will learn:
- The five building blocks to any successful organizational transformation
- Best practices to shift people, mindsets, and performance
- How to successfully blend business strategy with project management skills
Upon completing the course, participants have the option to earn an organizational transformation micro-credential through a 30-question exam, to help solidify and apply their learned knowledge of transformation fundamentals. The online course and micro-credential are designed to support professionals during an organizational transformation and aid them in their own professional development by making them ambassadors for organizational change and helping to open doors to additional career opportunities and growth.
To learn more about Organizational Transformation: Foundation, powered by Brightline, as well as its corresponding micro-certification, visit pmi.org/organizational-transformation.
About Project Management Institute
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at https://www.pmi.org/ , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute .
About Brightline Initiative
Brightline® is a Project Management Institute (PMI) initiative together with leading global organizations dedicated to helping executives bridge the expensive and unproductive gap between strategy design and delivery. Brightline delivers insights and solutions that empower leaders to successfully transform their organization’s vision into reality through strategic initiative management.
Learn more at www.brightline.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom